# Precision Medicine for mNETs: Update on Organoid Research



**Terence P. Gade MD PhD** 

Departments of Radiology and Cancer Biology Perelman School of Medicine, University of Pennsylvania 9<sup>th</sup> Annual Focus on Neuroendocrine Tumor 6 March 2020


# DISCLOSURES

- Trisalus Life Sciences- Scientific Advisory Board
- Grant Funding
  - NIH
  - Veterans Administration
  - Society of Interventional Oncology
  - Society of Interventional Radiology
  - RSNA




# **NETS: A GROWING HEALTH PROBLEM**

#### **Increasing Incidence of NET**



#### Metastatic Disease is Common






## THERAPEUTIC TARGETING OF MNETS: CHALLENGES





# Penn mNET Biopsy Protocol





# Model Generation: Organoids

Tumor Organoids Provide Unique Cancer Models


- Self-organizing 3D structures grown *in vitro*
- Recapitulate the architecture and function of the parent human tumor
- Diverse applications
  - Study of representative cancer biology
  - Precision medicine
    - Identify optimal therapy for each patient



Schematic of Tumor Organoid




## MNET ORGANOID CREATION: CHALLENGES





## MNET ORGANOID CREATION: PROGRESS Optimized Culture Conditions




## PRECISION MEDICINE

Personalized therapy against specific vulnerabilities in each patient's cancer

#### Key Components


- Consistent acquisition of tissue samples
- Safety & compatibility with current clinical workflow
- Robust patient-derived models (organoids)



The right drug for the right patient



## PARADIGM



## Precision Medicine: Patients 17 & 20

44 Hits that overlap

Class Catalog No. Targets

ATPase


lonCh \$1478

Product Name


Oligomycin A

					Oligomycin A	IonCh S1478	ATPase		
					Gemcitabine GZD824	cancer S1714 kinase S7194	Autophagy,DNA/RNA Bcr-Abl	Synthesis	
	15 Hite unique	a to Dat	iont 17	111000	Dinaciclib (SC 2795	kinase \$2768		+ 20 /	120121
	15 Hitseuniqu	elura	aitean t t th	(101020		unique	T QA/FNA CHLSB	ent zu (	M2842)
					Panobinostat (LBH589)	epigenetic \$1030	HDAC		
Biopsy	Product Name	Class 🗋	Catalog No.	Targets	■1 <sup>Q824</sup> ( isinos Product Nam	e	💽 Class 📑	🔨 Catalog No	. 💌 Targets 🚽
	PHA-793887	kinase	S1487	CDK	<sup>midep</sup> Deguelin			S8132	Akt
	Celecoxib	cancer	S1261	сох	Chetomin KPT-2276	\$7939 cancer \$2639	HIF LORSCH	\$7251	CRM1
+	PP121	kinase	S2622	DNA-PK,F	PD <sup>04929</sup> Poziotinib (HN	V781-36B)		S7358	EGFR
	I-BET151 (GSK120151A)	epigenet	tic S2 <b>780</b>	Epigenet	ic P990 (Will Bresib (A	BBV-075)097	HSP (e.g. HSP90)	S8400	Epigenetic f
Cell isolation &	GW9508	cancer	S8014	GPR	74392 17-AAG (Tane		cancer	S1141	HSP (e.g. H
expansion	Atorvastatin Calcium	netabol	is \$2077	HMG-Co.	AvihulastinBMS-707035	cancer S1248	Microrun WerASDIN		Integrase
	BI-847325		\$7843	MEK	blasti BAY 1217389			\$8215	Kinesin
	Pimasertib (AS-703026)	kinase_	S1475	MEK	Cucurbitacin B Nocodazo	S8165 cancer S2775	Microtubule Associate		p97
Validation	Cephalomannine	other	S2408	Others	ptolide (PG490)	cancer \$1241 cancer \$3604	Microtubule Associate Others	ed,Autophagy	
	Elaiophylin	microbio	1051448	Others	Nanchangmycin	microbiol \$1450	Others		
					Monomethyl auristatin E (MMAE)	\$7721 \$8144	Others Others		
	Apigenin	metabol		P450 (e.g	5. Cofuginone	kinase \$1363	PDGFR,c-Kit,VEGFR		
	VS-5584 (SB2343)	8	S7016	PI3K	CUDC-907	kinase \$2759	PI3K,HDAC		
	EHop-016	kinase	\$7319	Rac	RC T226 (NVP-BGT226) N0905	kinase S2749 S2898	PI3K,mTOR PLK		
		Kindse			IVII.N2238	cancer S2180	Proteasome		
	Dasatinib Monohydrate		S7782	Src	Bortezomib (PS-341) rfilzomib (PR-171)	cancer S1013 Protease S2853	Proteasome Proteasome		
Screen	QNZ (EVP4593)	cancer	S4902	TNF-alph	rozomib (ONX 0912)	Protease \$2853 Protease \$7049	Proteasome		
			0.002		CEP-18770 (Delanzomib)	Protease \$1157	Proteasome		
	Patient 17M				Epoxomicin	\$7038	Proteasome		
					KX2-391 Camptothecin	kinase S2700 cancer S1288	Src Topoisomerase		
					SN-38	cancer \$4908	Topoisomerase		
					Idarubicin HCI	cancer \$1228	Topoisomerase		
					(S)-10-Hydroxycamptothecin	\$2423	Topoisomerase	<b></b>	
					NPI-2358 (Plinabulin)	cancer \$1176	VDA		
								Y	IAD
								Penr	IR $LAD$

## Precision Medicine: Patients 17 & 20



### Precision Medicine: Patients 17 & 20





# SUMMARY

 Feasible to establish mNET organoid cultures from needle biopsy samples



Drug screening enables identification of existing,
FDA-approved drugs on a patient-by-patient basis

#### Foundation for precision medicine approach to mNET



## FUTURE DIRECTIONS: DEVELOPMENT FOR CLINICAL IMPLEMENTATION

Optimize culture of, and validate, *in vitro* (organoid) & *in vivo* models



## FUTURE DIRECTIONS: DEVELOPMENT FOR CLINICAL IMPLEMENTATION

Optimize culture of, and validate, *in vitro* (organoid) models

Leverage models for precision medicine paradigm for patients with mNETs



## Acknowledgements

### **Patient Volunteers**

#### **PIGI Lab**

Penn IR

Dan Ackerman

**Kelley Weinfurtner** 

**Michael Soulen** 

Greg Nadolski

Stephen Hunt

James Chen

Tony Secreto Josh Glover

#### **HT Screening Core**

Stem Cell & Xenograft Core Funding

Sara Cherry David Schultz





### Philanthropy

**Rick Mainwaring** 

